title: Differential inflammatory response to inhaled lipopolysaccharide targeted either to the airways or the alveoli in man.
abstract: Endotoxin (Lipopolysaccharide, LPS) is a potent inducer of inflammation and there is various LPS contamination in the environment, being a trigger of lung diseases and exacerbation. The objective of this study was to assess the time course of inflammation and the sensitivities of the airways and alveoli to targeted LPS inhalation in order to understand the role of LPS challenge in airway disease.In healthy volunteers without any bronchial hyperresponsiveness we targeted sequentially 1, 5 and 20 µg LPS to the airways and 5 µg LPS to the alveoli using controlled aerosol bolus inhalation. Inflammatory parameters were assessed during a 72 h time period. LPS deposited in the airways induced dose dependent systemic responses with increases of blood neutrophils (peaking at 6 h), Interleukin-6 (peaking at 6 h), body temperature (peaking at 12 h), and CRP (peaking at 24 h). 5 µg LPS targeted to the alveoli caused significantly stronger effects compared to 5 µg airway LPS deposition. Local responses were studied by measuring lung function (FEV(1)) and reactive oxygen production, assessed by hydrogen peroxide (H(2)O(2)) in fractionated exhaled breath condensate (EBC). FEV(1) showed a dose dependent decline, with lowest values at 12 h post LPS challenge. There was a significant 2-fold H(2)O(2) induction in airway-EBC at 2 h post LPS inhalation. Alveolar LPS targeting resulted in the induction of very low levels of EBC-H(2)O(2).Targeting LPS to the alveoli leads to stronger systemic responses compared to airway LPS targeting. Targeted LPS inhalation may provide a novel model of airway inflammation for studying the role of LPS contamination of air pollution in lung diseases, exacerbation and anti-inflammatory drugs.
authors.affiliation: Comprehensive Pneumology Center and Institute for Lung Biology and Disease-Helmholtz Zentrum München, Neuherberg, Germany. moeller@helmholtz-muenchen.de
authors.forename: Winfried
authors.initials: W
authors.lastname: Möller
authors.forename: Irene
authors.initials: I
authors.lastname: Heimbeck
authors.forename: Thomas P J
authors.initials: TP
authors.lastname: Hofer
authors.forename: Gülnaz
authors.initials: G
authors.lastname: Khadem Saba
authors.forename: Margot
authors.initials: M
authors.lastname: Neiswirth
authors.forename: Marion
authors.initials: M
authors.lastname: Frankenberger
authors.forename: Löms
authors.initials: L
authors.lastname: Ziegler-Heitbrock
mesh_terms: D000280:Administration, Inhalation; D001980:Bronchi / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D016535:Bronchial Hyperreactivity / Q000139:chemically induced* / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism; D005260:Female; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000633:toxicity*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000166:cytology / Q000378:metabolism; D011014:Pneumonia / Q000139:chemically induced* / Q000378:metabolism; D011650:Pulmonary Alveoli / Q000187:drug effects*; D012129:Respiratory Function Tests; D012137:Respiratory System / Q000187:drug effects*
chemical_list: D015850:Interleukin-6; D008070:Lipopolysaccharides; D002097:C-Reactive Protein; D006861:Hydrogen Peroxide